Display options
Cite
Abe K, Maeda Y, Matsuzaki C, et al. Bilirubin is inversely related to diabetic peripheral neuropathy assessed by sural nerve conduction study. J Diabetes Investig. 2021;12(11):2028-2035doi: 10.1111/jdi.13568.
Abe, K., Maeda, Y., Matsuzaki, C., Yokomizo, H., Inoue, T., Sonoda, N., Ogawa, Y., & Inoguchi, T. (2021). Bilirubin is inversely related to diabetic peripheral neuropathy assessed by sural nerve conduction study. Journal of diabetes investigation, 12(11), 2028-2035. https://doi.org/10.1111/jdi.13568
Abe, Kentaro, et al. "Bilirubin is inversely related to diabetic peripheral neuropathy assessed by sural nerve conduction study." Journal of diabetes investigation vol. 12,11 (2021): 2028-2035. doi: https://doi.org/10.1111/jdi.13568
Abe K, Maeda Y, Matsuzaki C, Yokomizo H, Inoue T, Sonoda N, Ogawa Y, Inoguchi T. Bilirubin is inversely related to diabetic peripheral neuropathy assessed by sural nerve conduction study. J Diabetes Investig. 2021 Nov;12(11):2028-2035. doi: 10.1111/jdi.13568. Epub 2021 May 20. PMID: 33949141; PMCID: PMC8565409.
Copy Download .nbib Format: NLM
Share it on

J Diabetes Investig. 2021 Nov;12(11):2028-2035. doi: 10.1111/jdi.13568. Epub 2021 May 20.

Bilirubin is inversely related to diabetic peripheral neuropathy assessed by sural nerve conduction study.

Journal of diabetes investigation

Kentaro Abe, Yasutaka Maeda, Chitose Matsuzaki, Hisashi Yokomizo, Tomoaki Inoue, Noriyuki Sonoda, Yoshihiro Ogawa, Toyoshi Inoguchi

Affiliations

  1. Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  2. Department of Diabetes, Endocrinology and Metabolism, National Hospital Organization Kokura Medical Center, Kitakyusyu, Japan.
  3. Minami Diabetes Clinical Research Center, Fukuoka, Japan.
  4. Department of Endocrine, Metabolism and Diabetes, Kyushu University Hospital, Fukuoka, Japan.
  5. Fukuoka City Health Promotion Support Center, Fukuoka, Japan.

PMID: 33949141 PMCID: PMC8565409 DOI: 10.1111/jdi.13568

Abstract

AIMS/INTRODUCTION: Diagnosis of diabetic peripheral neuropathy (DPN) depends on subjective findings, certain investigations for DPN risks have not been performed enough. Bilirubin protects against vascular complications by reducing oxidative stress in diabetes, but is not fully tested for DPN. This study aimed to evaluate sural nerve conduction impairments (SNCI) as an objective DPN marker and the contribution of bilirubin to SNCI.

MATERIALS AND METHODS: Using DPN-Check

RESULTS: The incidence of SNCI was 72.0%. The sensitivity and specificity of SNCI for DPN prediagnosis by simplified criteria were 54.6 and 90.5%, respectively, and similarly corresponded with diabetic retinopathy and nephropathy (sensitivity 57.4 and 50.0%, respectively). SNCI significantly related to diabetes duration, declined estimated glomerular filtration rate, albuminuria and total bilirubin. SNCI incidence was attenuated in the higher bilirubin tertiles (89.8/65.3/54.8%, P < 0.001). Bilirubin was an independent inverse risk factor for SNCI, even after adjustment by known risk factors for DPN and markers for microvascular complications.

CONCLUSIONS: SNCI is a comprehensive marker for diabetic complications. We first showed the independent inverse relationship between bilirubin and SNCI through the independent pathway with other complications, provably reducing oxidative stress, as previously reported.

© 2021 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.

Keywords: Bilirubin; Diabetic neuropathies; Oxidative stress

References

  1. J Diabetes Investig. 2018 Sep;9(5):1173-1181 - PubMed
  2. J Neurol Neurosurg Psychiatry. 1970 Aug;33(4):442-52 - PubMed
  3. Diabetes Care. 2017 Jan;40(1):136-154 - PubMed
  4. Diabetes. 2014 Aug;63(8):2845-53 - PubMed
  5. J Clin Invest. 2003 Feb;111(4):431-3 - PubMed
  6. J Clin Invest. 1995 Aug;96(2):1159-63 - PubMed
  7. J Neurol Neurosurg Psychiatry. 1977 Nov;40(11):1072-82 - PubMed
  8. Science. 1987 Feb 27;235(4792):1043-6 - PubMed
  9. Neurology. 1993 Apr;43(4):817-24 - PubMed
  10. N Engl J Med. 1993 Sep 30;329(14):977-86 - PubMed
  11. Endocrine. 2015 Nov;50(2):405-12 - PubMed
  12. Diabetes Care. 2004 Sep;27(9):2178-83 - PubMed
  13. Mol Biol Rep. 2012 Sep;39(9):8669-78 - PubMed
  14. Diabetol Metab Syndr. 2018 Sep 12;10:69 - PubMed
  15. Kidney Int. 2008 Nov;74(9):1197-201 - PubMed
  16. JAMA. 2007 Sep 26;298(12):1398-400 - PubMed
  17. J Diabetes Investig. 2020 Jan;11(1):5-16 - PubMed
  18. Diabetes. 2000 Jun;49(6):1006-15 - PubMed
  19. Diabetes Ther. 2018 Feb;9(1):331-338 - PubMed
  20. Diabetes Care. 2008 Mar;31(3):522-4 - PubMed
  21. J Diabetes Investig. 2019 Sep;10(5):1291-1298 - PubMed
  22. J Clin Epidemiol. 2000 May;53(5):519-23 - PubMed
  23. Diabetes Care. 2006 Feb;29(2):340-4 - PubMed
  24. Cell Biochem Biophys. 2015 Apr;71(3):1425-43 - PubMed
  25. PLoS One. 2014 Jan 22;9(1):e86515 - PubMed
  26. Diabetes Care. 2006 Sep;29(9):2023-7 - PubMed
  27. Diabetes. 1977 Jun;26(6):546-50 - PubMed
  28. Diabetes Metab J. 2012 Dec;36(6):443-51 - PubMed
  29. Sci Rep. 2017 Jan 30;7:41681 - PubMed
  30. Kidney Int. 2010 Nov;78(9):905-19 - PubMed
  31. Sci Rep. 2016 Nov 02;6:36437 - PubMed
  32. Am J Med. 2008 Sep;121(9):781-788.e1 - PubMed
  33. Acta Diabetol. 2015 Feb;52(1):65-72 - PubMed
  34. Ophthalmology. 2011 Jul;118(7):1423-8 - PubMed
  35. Lancet. 2005 Oct 15-21;366(9494):1340-3 - PubMed
  36. Diabetes. 2007 Aug;56(8):2148-54 - PubMed

Publication Types

Grant support